{6-[(Diphenylcarbamoyloxy)-methyl]-7,8-dihydro-naphthalen-1-yloxy}-acetic acid | 782427-08-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {6-[(Diphenylcarbamoyloxy)-methyl]-7,8-dihydro-naphthalen-1-yloxy}-acetic acid
• 英文别名: 2-[[6-(Diphenylcarbamoyloxymethyl)-7,8-dihydronaphthalen-1-yl]oxy]acetic acid
• CAS: 782427-08-1
• 化学式: C₂₆H₂₃NO₅
• 分子量: 429.472
• InChiKey: ZSJIPPDUEJOCNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {6-[(Diphenylcarbamoyloxy)-methyl]-7,8-dihydro-naphthalen-1-yloxy}-acetic acid 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 以71%的产率得到[5-(carboxymethoxy)-1,2,3,4-tetrahydro-2-naphthyl]methyl N,N-diphenylcarbamate
  参考文献：
  名称：

  Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3

  摘要：

  The new classes of diphenylcarbamate derivatives with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered. The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K-i values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family. Compound (R)-4 was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.047
• 作为产物：
  描述：

  5-t-butyldiphenylsilyloxy-2-hydroxymethyl-3,4-dihydronaphthalene 在 吡啶 、 sodium hydroxide 、 四丁基氟化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 {6-[(Diphenylcarbamoyloxy)-methyl]-7,8-dihydro-naphthalen-1-yloxy}-acetic acid
  参考文献：
  名称：

  Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3

  摘要：

  The new classes of diphenylcarbamate derivatives with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered. The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K-i values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family. Compound (R)-4 was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.047

文献信息

• NAPHTHALENE DERIVATIVES AS PROSTAGLANDIN I2 AGONISTS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0749424B1

  公开（公告）日：2001-09-12
• Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3
  作者：Kouji Hattori、Akira Tanaka、Osamu Okitsu、Seiichiro Tabuchi、Kiyoshi Taniguchi、Mie Nishio、Satoshi Koyama、Masahide Higaki、Jiro Seki、Kazuo Sakane

  DOI：10.1016/j.bmcl.2005.04.047

  日期：2005.6

  The new classes of diphenylcarbamate derivatives with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered. The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K-i values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family. Compound (R)-4 was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers. (c) 2005 Elsevier Ltd. All rights reserved.